Joanne Curley - 19 Jul 2022 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Development Officer
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
19 Jul 2022
Net transactions value
-$131,384
Form type
4
Filing time
20 Jul 2022, 16:08:47 UTC
Previous filing
15 Jul 2022
Next filing
04 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $34,311 +5,384 +29% $6.37 23,657 19 Jul 2022 Direct
transaction VERA Class A Common Stock Sale $86,229 -5,384 -23% $16.02 18,273 19 Jul 2022 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $38.24 +6 +0.03% $6.37 18,279 19 Jul 2022 Direct
transaction VERA Class A Common Stock Sale $99.3 -6 -0.03% $16.55 18,273 19 Jul 2022 Direct F1
transaction VERA Class A Common Stock Options Exercise $17,514 +6,046 +33% $2.90* 24,319 19 Jul 2022 Direct
transaction VERA Class A Common Stock Sale $96,810 -6,046 -25% $16.01 18,273 19 Jul 2022 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $23.17 +8 +0.04% $2.90* 18,281 19 Jul 2022 Direct
transaction VERA Class A Common Stock Sale $132 -8 -0.04% $16.54 18,273 19 Jul 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -5,390 -28% $0.000000 14,029 19 Jul 2022 Class A Common Stock 5,390 $6.37 Direct F4
transaction VERA Stock Option (right to buy) Options Exercise $0 -6,054 -11% $0.000000 46,759 19 Jul 2022 Class A Common Stock 6,054 $2.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 13, 2022.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.46 to $16.45, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.53 to $16.56, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on March 12, 2021, and 1/48 of the shares vest monthly thereafter.
F5 1/4 of the shares subject to the option vest on December 16, 2021, and 1/48 of the shares vest monthly thereafter.